CN Patent

CN105503828A — 一种吡咯衍生物的富马酸盐的制备方法

Assigned to BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co Ltd · Expires 2016-04-20 · 10y expired

What this patent protects

本发明涉及以3-腈基-5-(2-氟-苯基)-1-(吡啶-3-磺酰基)-1H-吡咯(2)为起始原料，以Pd/C加氢还原，得到3-胺甲基-5-(2-氟-苯基)-1-(吡啶-3-磺酰基)-1H-比咯(3)；3与多聚甲醛在硼氢化钠还原后，再与富马酸成盐，得到最终化合物富马酸沃诺拉赞(1)；此制备方法简便易行、收率高，质量好，便于工业化生产。

USPTO Abstract

本发明涉及以3-腈基-5-(2-氟-苯基)-1-(吡啶-3-磺酰基)-1H-吡咯(2)为起始原料，以Pd/C加氢还原，得到3-胺甲基-5-(2-氟-苯基)-1-(吡啶-3-磺酰基)-1H-比咯(3)；3与多聚甲醛在硼氢化钠还原后，再与富马酸成盐，得到最终化合物富马酸沃诺拉赞(1)；此制备方法简便易行、收率高，质量好，便于工业化生产。

Drugs covered by this patent

vonoprazan-fumarate (VONOPRAZAN FUMARATE)

Patent Metadata

Patent number: CN105503828A
Jurisdiction: CN
Classification: —
Expires: 2016-04-20
Drug substance claim: No
Drug product claim: No
Assignee: BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.